| 2026-08-11 | Press release | BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-11 | Press release | BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress |
| 2026-05-12 | Press release | BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-12 | Press release | BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress |
| 2026-04-22 | Press release | BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant |
| 2026-04-22 | Press release | BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Of |
| 2026-04-21 | Press release | BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the |
| 2026-04-21 | Presentation | The RAS:PI3Kα Breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2AMP models through non-canonical RAS signaling blocka |
| 2026-04-20 | Press release | BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant |
| 2026-04-13 | Press release | BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-18 | Press release | BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 |
| 2026-03-06 | Press release | BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Sel |
| 2026-03-05 | Press release | BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress |
| 2026-02-12 | Press release | BBOT to Participate in Upcoming Investor Healthcare Conferences |
| 2026-02-06 | Presentation | BBOT Corporate Deck |
| 2026-01-12 | Presentation | BridgeBio-Corporate-Presentation-January-2026.pdf |
| 2026-01-07 | Press release | BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline P |
| 2025-12-02 | Presentation | BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fu |
| 2025-11-19 | Presentation | BREAKER-101: A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-1 |
| 2025-07-21 | Press release | BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer |
| 2025-06-12 | Press release | BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BB |
| 2025-05-09 | Presentation | BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficac |
| 2025-04-01 | Press release | BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanc |
| 2025-02-28 | Press release | BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create |
| 2024-12-23 | Press release | BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 |
| 2024-12-11 | Presentation | BBO-10203, a first-in-class, orally bioavailable, selective blocker of the PI3Kα:RAS interaction inhibits tumor growth a |
| 2024-12-09 | Press release | BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provid |
| 2024-11-18 | Press release | BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Direct |
| 2024-10-30 | Press release | BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, |
| 2024-10-24 | Presentation | BBO-8520, a first-in-class, direct, and covalent small molecule inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C |
| 2024-10-23 | Presentation | BBO-11818, an orally bioavailable, highly potent and non covalent pan-KRAS inhibitor demonstrates robust anti-tumor acti |
| 2024-10-08 | Presentation | BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust |
| 2024-10-08 | Presentation | BBO-11818: an orally bioavailable, highly potent and selective noncovalent pan-KRAS(ON) and (OFF) inhibitor with robust |
| 2024-10-08 | Presentation | BBO-11818, an orally bioavailable, highly potent and non-covalent pan-KRAS inhibitor demonstrates robust anti-tumor acti |
| 2024-09-09 | Press release | BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Offic |
| 2024-06-06 | Press release | BridgeBio Oncology Therapeutics announces first patient dosed with BBO-8520 in the Ph. 1 ONKORAS-101 trial for KRASG12C |
| 2024-01-09 | Press release | BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRASG12C-Mutated Metasta |
| 2023-09-01 | Presentation | Targeting RAS-Driven PI3Kα Activation in Human Tumors |